Home⇛The PCMC Journal⇛vol. 15 no. 2 (2019)

Clinical Efficacy of Chlorhexidine 0.12% Spray versus ChlorhexidineMouth Rinse on Plaque Control and Gingival Health in HealthyPediatric Patients: A Randomized Controlled Trial

Malin A. Mandanas | Karyl Grace E. Bautista

 

Abstract:

BACKGROUND: Difficulties in providing proper oral health hygiene is accentuated in special populations. Effective plaque control is necessary to minimize the potential risks of dental disease. Chlorhexidine (CHX) mouth rinse is an efficacious means of plaque control yet may be difficult to use.. OBJECTIVES: To compare the clinical efficacy of 0.12% CHX spray versus 0.12% CHX mouth rinse on existing supragingival plaque and gingivitis in a group of healthy pediatric patients. METHODS: This is a randomized, controlled, single blind, open label clinical trial. Participants were assigned by simple randomization to: (1) Group A used 0.12 CHX mouth rinse, and (2) Group B administered 0.12% CHX spray, to be used for a period of 4 weeks or 28 days. RESULTS: 28 children were included in the analysis. After 4 weeks of CHX use, there was no difference in the gingival status. Within the mouth rinse group, the plaque scoring index (from 3 to 2, p value =0.005) and the plaque severity index (from 0.65 to 0.51, p value =0.017) decreased. While in the spray group, only the plaque severity index had significant decrease (from 0.55 to 0.46, p value =0.019). CONCLUSIONS: CHX spray delivery system is an efficacious method in decreasing plaque severity and is comparable to plaque reduction seen with the use of mouth rinse. The decrease/maintenance in gingival index values proves that there is no progress in gingivitis disease process. RECOMMENDATIONS: CHX spray has been proven to reduce plaque severity and should be considered as an adjunct of oral hygiene maintenance for children.



References:

  1. Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. J Dent Res. 2014 Aug 23;XX(X):1-9.
  2. Petersen PE, Ogawa H. Strengthening the prevention of periodontal disease: the WHO approach. J Periodontol. 2005 Dec;76:2187-93.
  3. American Academy of Periodontology, Committee on Research, Science and Therapy. The pathogenesis of periodontal diseases. J Periodontol. 1999 Apr;70:457-70.
  4. American Academy of Periodontology, Committee on Research, Science and Therapy. Periodontal maintenance. J Periodontol. 2003 Sep;74:1395-401.
  5. Varoni E, Tarce M, Lodi G, Carrassi A. Chlorhexidine (CHX) in dentistry: state of the art. Minerva Stomatol. 2012 Sep;61:499-419.
  6. Gunsolley JC. A meta-analysis of six-month studies of antiplaque and antigingivitis agents. J Am Dent Assoc. 2006 Dec;137(12):1649-57.
  7. Al-Tannir MA, Goodman HS. A review of chlorhexidine and its use in special populations. Spec Care Dentist. 1994;14(3):116-22.
  8. Jenkins S, Addy M, Wade W. The mechanism of action of chlorhexidine. A study of plaque growth on enamel inserts in vivo. J Clin Periodontol. 1988;15:415-24.
  9. World Health Organization. Oral health. 2012 Apr. Available from: http://www.who.int/mediacentre/factsheets/fs318/en/
  10. Balagopal S, Arjunkumar R. Chlorhexidine: the gold standard antiplaque agent. J Pharm Sci Res. 2013;5(12):270-4.
  11. Krayer JW, Kirkwood KL. Non-surgical chemotherapeutic treatment strategies for the management of periodontal diseases. Dent Clin North Am. 2010;54:13-33.
  12. Francis JR, Addy M, Hunter B. A comparison of three delivery methods of chlorhexidine in handicapped children. II. Parent and house-parent preferences. J Periodontol. 1987 Jul;58(7):456-9.
  13. Al-Allaq T, DeBord TK, Liu H, Wang Y, Messadi D. Oral health status of individuals with cerebral palsy at a nationally recognized rehabilitation center. Spec Care Dentist. 2015;35(1):15-21.
  14. Guare RDO, Ciampioni AL. Prevalence of periodontal disease in the primary dentition of children with cerebral palsy. J Dent Child. 2004;71(1):27-32.
  15. Glassman P, Anderson M, Jacobsen P, Schonfeld S, Weintraub J, White A, et al. Practical protocols for the prevention of dental disease in community settings for people with special needs: the protocols. Spec Care Dentist. 2003;23(5):160-4.
  16. Löe H, Schiott CR. The effect of mouthrinses and topical application of chlorhexidine on the development of dental plaque and gingivitis in man. J Periodontal Res. 1970;5:79-83.
  17. National Center for Biotechnology Information. PubChem Compound Database; CID=9552079. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/9552079
  18. National Center for Biotechnology Information. PubChem Compound Database; CID=9552081. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/9552081
  19. Drugs.com. Chlorhexidine. 2016 Sept. Available from: https://www.drugs.com/pro/chlorhexidine.html
  20. Neto CAF, Parolo CCF, Rösing CK, Maltz M. Comparative analysis of the effect of two chlorhexidine mouthrinses on plaque accumulation and gingival bleeding. Braz Oral Res. 2008;22(2):139-44.
  21. Najafi MH, Taheri M, Mokhtari MR, Forouzanfar A, Farazi F, Mirzaee M, et al. Comparative study of 0.2% and 0.12% digluconate chlorhexidine mouth rinses on the level of dental staining and gingival indices. Dent Res J. 2012 May;9(3):305-8.
  22. Montiel JM. Efficacy of two antiplaque and antigingivitis treatments in a group of young mentally retarded patients. Med Oral. 2002 Mar-Apr;7(2):60-3.
  23. Panagakos FS, Volpe AR, Petrone ME, DeVizio W, Davies RM, Colgate-Palmolive Technology Center, et al. Advanced oral antibacterial/anti-inflammatory technology: a comprehensive review of the clinical benefits of a triclosan/copolymer/fluoride dentifrice. J Clin Dent. 2005;XVI Suppl:S1-S20.
  24. Burtner AP, Low DW, McNeal DR, Hassell TM, Smith RG. Effects of chlorhexidine spray on plaque and gingival health in institutionalized persons with mental retardation. Spec Care Dentist. 1991;11(3):97-100.
  25. Clavero J, Baca P, Junco P, Gonzalez P. Effects of 0.2% chlorhexidine spray applied once or twice daily on plaque accumulation and gingival inflammation in a geriatric population. J Clin Periodontol. 2003;30:773-7.
  26. Gunsolley JC. Clinical efficacy of antimicrobial mouthrinses. J Dent. 2010;38 Suppl 1:S6-S10.
  27. Mälmo University. Quigley Hein Index (modified). Available from: https://www.mah.se/CAPP/Methods-and-Indices/Oral-Hygiene-Indices/Quigely-Hein-Index-modified/
  28. Wei SHY, Lang KP. Periodontal epidemiological indices for children and adolescents: I. gingival and periodontal health assessments. Pediatr Dent. 1981;3(4):353-60.
  29. Northern Arizona University. Indices and data collection. 2000. Available from: http://jan.ucc.nau.edu/~tsm/dh450/class/methods/data/lesson2-4-1.html
  30. Machin D, Fayers PM. Randomized clinical trials: design, practice and reporting. Wiley-Blackwell; 2010. Chapter 9: Trial size, p. 184, 191.
  31. Pizzo G, Guiglia R, Imburgia M, Pizzo I, D’Angelo M, Giuliana G. The effects of antimicrobial sprays and mouthrinses on supragingival plaque regrowth: a comparative study. J Periodontol. 2006;77(2):248-56.
  32. Drugs.com. Chlorhexidine gluconate mouthspray. 2018 Jan. Available from: https://www.drugs.com/uk/chlorhexidine-gluconate-mouthspray-leaflet.html
  33. BioMed Central. Dental plaque as a biofilm and a microbial community – implications for health and disease. BMC Oral Health. 2006;6(Suppl 1):S14.
  34. Informed Health Online (Internet). Gingivitis and periodontitis: overview. Institute for Quality and Efficiency in Health Care: Germany; 2006.
  35. Republic of the Philippines, Bureau of Food and Drugs, Department of Health. Bureau Circular No. 12 series 1997. Available from: https://ww2.fda.gov.ph/attachments/article/28771/bc%2012%20s%201997.pdf

Tools


Copyright © 2025  KITE Digital Educational Solutions |  Exclusively distributed by CE-Logic